Anne Angiolillo

5.1k total citations · 1 hit paper
76 papers, 2.7k citations indexed

About

Anne Angiolillo is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Hematology. According to data from OpenAlex, Anne Angiolillo has authored 76 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Public Health, Environmental and Occupational Health, 35 papers in Pediatrics, Perinatology and Child Health and 21 papers in Hematology. Recurrent topics in Anne Angiolillo's work include Acute Lymphoblastic Leukemia research (43 papers), Childhood Cancer Survivors' Quality of Life (33 papers) and Lymphoma Diagnosis and Treatment (11 papers). Anne Angiolillo is often cited by papers focused on Acute Lymphoblastic Leukemia research (43 papers), Childhood Cancer Survivors' Quality of Life (33 papers) and Lymphoma Diagnosis and Treatment (11 papers). Anne Angiolillo collaborates with scholars based in United States, Canada and Australia. Anne Angiolillo's co-authors include Giovanna Tosato, Cecilia Sgadari, Gregory H. Reaman, Joshua Μ. Farber, Fang Liao, Hynda K. Kleinman, D D Taub, William L. Carroll, Stephen P. Hunger and Meenakshi Devidas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Anne Angiolillo

74 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.

1995 594 citations Anne Angiolillo, Cecilia Sgadari et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne Angiolillo United States	22	915	814	807	647	523	76	2.7k
Virginie Gandemer France	31	607 0.7×	308 0.4×	1.2k 1.5×	818 1.3×	439 0.8×	139	2.7k
Carmella van de Ven United States	31	891 1.0×	1.1k 1.3×	503 0.6×	295 0.5×	320 0.6×	151	2.9k
Patrick Lutz France	26	490 0.5×	326 0.4×	462 0.6×	303 0.5×	374 0.7×	62	2.3k
Stuart S. Winter United States	31	640 0.7×	402 0.5×	1.2k 1.5×	607 0.9×	809 1.5×	107	2.7k
G Souillet France	29	448 0.5×	486 0.6×	444 0.6×	366 0.6×	312 0.6×	105	2.8k
Masahiro Tsuchida Japan	34	963 1.1×	944 1.2×	1.2k 1.4×	503 0.8×	736 1.4×	160	4.3k
Dirk Schwabe Germany	30	1.2k 1.4×	1.4k 1.7×	633 0.8×	358 0.6×	683 1.3×	105	3.7k
Alina Ferster Belgium	30	318 0.3×	654 0.8×	820 1.0×	923 1.4×	521 1.0×	151	3.8k
Jun Okamura Japan	30	687 0.8×	719 0.9×	377 0.5×	423 0.7×	509 1.0×	196	3.3k
Andreas Hirt Switzerland	26	598 0.7×	856 1.1×	321 0.4×	325 0.5×	312 0.6×	89	3.1k

Countries citing papers authored by Anne Angiolillo

Since Specialization

Citations

This map shows the geographic impact of Anne Angiolillo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne Angiolillo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne Angiolillo more than expected).

Fields of papers citing papers by Anne Angiolillo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne Angiolillo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne Angiolillo. The network helps show where Anne Angiolillo may publish in the future.

Co-authorship network of co-authors of Anne Angiolillo

This figure shows the co-authorship network connecting the top 25 collaborators of Anne Angiolillo. A scholar is included among the top collaborators of Anne Angiolillo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne Angiolillo. Anne Angiolillo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Benjamin D., Curtis A. Lachowiez, Alexander J. Ambinder, et al.. (2024). Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML - a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax. Blood. 144(Supplement 1). 2855–2855. 1 indexed citations

Hibbitts, Emily, Meenakshi Devidas, Moira K. Whitley, et al.. (2023). Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer. 70(11). e30634–e30634. 2 indexed citations

Elgarten, Caitlin W., John A. Kairalla, Joel Thompson, et al.. (2023). SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731. SHILAP Revista de lepidopterología. 4(3). 745–750. 2 indexed citations

Chen, Yanjun, Lindsey Hageman, Anne Angiolillo, et al.. (2023). Association between High Antimetabolite Dose Intensity during Maintenance, Toxicities and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): COG-AALL03N1 Report. Blood. 142(Supplement 1). 521–521. 1 indexed citations

Chen, Yanjun, Lindsey Hageman, Anne Angiolillo, et al.. (2023). Poverty and Relapse Risk in Children with Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL03N1 Report. Blood. 142(3). 221–229. 10 indexed citations

Chang, Ti‐Cheng, Wenan Chen, Stanley Pounds, et al.. (2023). Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.. Journal of Clinical Oncology. 41(16_suppl). 10015–10015. 1 indexed citations

Angiolillo, Anne, David A. Jacobsohn, Jinjun Cheng, et al.. (2023). Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation. Frontiers in Pediatrics. 11. 1067131–1067131. 1 indexed citations

Kairalla, John A., Emily Hibbitts, Meenakshi Devidas, et al.. (2022). Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. JNCI Journal of the National Cancer Institute. 114(8). 1167–1175. 12 indexed citations

Angiolillo, Anne, Reuven J. Schore, John A. Kairalla, et al.. (2019). Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932. Blood. 134(Supplement_1). 824–824. 4 indexed citations

10.

Zheng, Daniel J., Xiaomin Lu, Reuven J. Schore, et al.. (2017). Longitudinal analysis of quality‐of‐life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer. 124(3). 571–579. 29 indexed citations

11.

Wu, David, Ryan Emerson, Anna Sherwood, et al.. (2014). Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH. Clinical Cancer Research. 20(17). 4540–4548. 106 indexed citations

12.

Weaver, Meaghann S., Fariba Navid, Alison R. Huppmann, Holly J. Meany, & Anne Angiolillo. (2014). Vincristine and Dactinomycin in Infantile Myofibromatosis With a Review of Treatment Options. Journal of Pediatric Hematology/Oncology. 37(3). 237–241. 18 indexed citations

13.

Levy, Adam, Paul A. Meyers, Leonard H. Wexler, et al.. (2008). Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer. 115(1). 207–216. 10 indexed citations

14.

Miles, Rodney R., Mitchell S. Cairo, Prakash Satwani, et al.. (2007). Immunophenotypic identification of possible therapeutic targets in paediatric non‐Hodgkin lymphomas: a children's oncology group report. British Journal of Haematology. 138(4). 506–512. 11 indexed citations

15.

Simon, Christian, et al.. (2006). A survey of language barriers from the perspective of pediatric oncologists, interpreters, and parents. Pediatric Blood & Cancer. 47(6). 819–824. 83 indexed citations

16.

Angiolillo, Anne, Eric Kodish, Beverly J. Lange, et al.. (2004). Staged informed consent for a randomized clinical trial in childhood leukemia: Impact on the consent process. Pediatric Blood & Cancer. 42(5). 433–437. 40 indexed citations

17.

Young, Guy & Anne Angiolillo. (1999). Long-term treatment of refractory thrombocytopenia in a patient with wiskott-aldrich syndrome with vincristine, immunoglobulin, and methylprednisolone. American Journal of Hematology. 62(3). 183–185. 5 indexed citations

18.

Angiolillo, Anne, Cecilia Sgadari, & Giovanna Tosato. (1996). A Role for the Interferon‐Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin‐12. Annals of the New York Academy of Sciences. 795(1). 158–167. 94 indexed citations

19.

Angiolillo, Anne, Cecilia Sgadari, D D Taub, et al.. (1995). Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.. The Journal of Experimental Medicine. 182(1). 155–162. 594 indexed citations breakdown →

20.

Tosato, Giovanna, K Taga, Anne Angiolillo, & Cecilia Sgadari. (1995). 8 Epstein-Barr virus as an agent of haematological disease. Baillière s Clinical Haematology. 8(1). 165–199. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact